Repligen Corporation (RGEN)

Market Cap	7.49B
Revenue (ttm)	634.44M
Net Income (ttm)	-25.51M
Shares Out	56.15M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	80.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	841,198
Open	136.05
Previous Close	137.12
Day's Range	130.42 - 137.05
52-Week Range	113.50 - 184.98
Beta	0.95
Analysts	Buy
Price Target	177.78 (+33.26%)
Earnings Date	Apr 30, 2025

About RGEN

Repligen Corporation engages in the development and commercialization of bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are use...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1981
• Employees: 1,778
• Stock Exchange: NASDAQ
• Ticker Symbol: RGEN
• Website: https://www.repligen.com

Analyst Forecast

According to 12 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price forecast is $177.78, which is an increase of 33.26% from the latest price.

Price Target

$177.78

(33.26% upside)

Analyst Consensus: Buy